KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) FCF Margin: 2009-2025

Historic FCF Margin for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Sep 2025 value amounting to 26.52%.

  • Acadia Pharmaceuticals' FCF Margin rose 129.00% to 26.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 18.92%, marking a year-over-year decrease of 289.00%. This contributed to the annual value of 16.41% for FY2024, which is 1412.00% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' FCF Margin stood at 26.52%, which was up 9.71% from 24.17% recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' FCF Margin registered a high of 36.96% during Q4 2023, and its lowest value of -66.10% during Q1 2022.
  • Over the past 3 years, Acadia Pharmaceuticals' median FCF Margin value was 14.13% (recorded in 2024), while the average stood at 11.18%.
  • Within the past 5 years, the most significant YoY rise in Acadia Pharmaceuticals' FCF Margin was 5,444bps (2023), while the steepest drop was 2,729bps (2023).
  • Over the past 5 years, Acadia Pharmaceuticals' FCF Margin (Quarterly) stood at -17.68% in 2021, then increased by 21bps to -17.48% in 2022, then surged by 5,444bps to 36.96% in 2023, then plummeted by 2,158bps to 15.38% in 2024, then surged by 129bps to 26.52% in 2025.
  • Its FCF Margin was 26.52% in Q3 2025, compared to 24.17% in Q2 2025 and 8.32% in Q1 2025.